Literature DB >> 8227329

Mechanism of the anticoagulant effect of warfarin as evaluated in rabbits by selective depression of individual procoagulant vitamin K-dependent clotting factors.

A Zivelin1, L V Rao, S I Rapaport.   

Abstract

We have evaluated the contribution of depression of individual procoagulant vitamin K-dependent clotting factors to the ability of warfarin to protect rabbits against tissue factor-induced coagulation. Mean activities of individual procoagulant factors were determined, in assays with rabbit substrates, for a group of rabbits achieving a protective degree of anticoagulation with warfarin. Values were: factor VII, 12%; factor IX, 7%; factor X, 14%, and prothrombin, 13%. The effect upon tissue factor-induced coagulation of selective immunodepletion of each factor to a comparable level was then evaluated. Immunodepletion of plasma factor X or prothrombin, but not of factor VII or factor IX, protected otherwise normal rabbits against tissue factor-induced coagulation. Next, we determined the effect upon the protection in warfarin-treated rabbits of selectively restoring factor X or prothrombin before infusing tissue factor. When either factor was selectively restored, warfarin's protective effect was abolished. Moreover, selective restoration of prothrombin sensitized warfarin-treated rabbits to coagulation more severe than observed in nontreated control rabbits. One may extrapolate from these data that depression of both factor X and prothrombin are required for warfarin's clinical antithrombotic efficacy and that depression of plasma prothrombin is particularly important.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8227329      PMCID: PMC288391          DOI: 10.1172/JCI116814

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  31 in total

1.  A CLINICAL AND FAMILY STUDY OF HEREDITARY PROCONVERTIN (FACTOR VII) DEFICIENCY.

Authors:  C A HALL; S I RAPAPORT; S B AMES; J A DEGROOT
Journal:  Am J Med       Date:  1964-08       Impact factor: 4.965

2.  SURGERY IN PATIENTS WITH CONGENITAL FACTOR VII DEFICIENCY (CONGENITAL HYPOPROCONVERTINEMIA). EXPERIENCE WITH ONE CASE AND REVIEW OF THE LITERATURE.

Authors:  H S STRAUSS
Journal:  Blood       Date:  1965-03       Impact factor: 22.113

3.  Behaviour of factors II, VII, IX and X during long-term treatment with coumarin.

Authors:  E A LOELIGER; M J MATTERN; A S den BRABANDER
Journal:  Thromb Diath Haemorrh       Date:  1963-04-15

4.  Factor VII; its turnover rate and its possible role in thrombogenesis.

Authors:  E A LOELIGER; C ter HAAR; H L BOOIJ
Journal:  Thromb Diath Haemorrh       Date:  1960-03-01

5.  [Rapid physiological coagulation method in determination of fibrinogen].

Authors:  A CLAUSS
Journal:  Acta Haematol       Date:  1957-04       Impact factor: 2.195

6.  A sensitive, accurate assay for extrinsic pathway inhibitor (EPI) activity in rabbit plasma: paradoxical effect of excess exogenous factor X.

Authors:  T A Warr; L V Rao; S I Rapaport
Journal:  Thromb Res       Date:  1990-08-15       Impact factor: 3.944

7.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.

Authors:  H Towbin; T Staehelin; J Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1979-09       Impact factor: 11.205

8.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

9.  Randomized prospective trial comparing the native prothrombin antigen with the prothrombin time for monitoring oral anticoagulant therapy.

Authors:  B Furie; C F Diuguid; M Jacobs; D L Diuguid; B C Furie
Journal:  Blood       Date:  1990-01-15       Impact factor: 22.113

10.  The effect of sodium warfarin on rabbit monocyte tissue factor expression.

Authors:  R L Edwards; E Schreiber; W Brande
Journal:  Thromb Res       Date:  1986-04-15       Impact factor: 3.944

View more
  19 in total

1.  Prothrombotic phenotype of protein Z deficiency.

Authors:  Z F Yin; Z F Huang; J Cui; R Fiehler; N Lasky; D Ginsburg; G J Broze
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

2.  Monitoring anticoagulation in patients with an unreliable prothrombin time/international normalized ratio: factor II versus chromogenic factor X testing.

Authors:  Lisa M Baumann Kreuziger; Yvonne H Datta; Andrew D Johnson; Nicole D Zantek; Ryan Shanley; Mark T Reding
Journal:  Blood Coagul Fibrinolysis       Date:  2014-04       Impact factor: 1.276

Review 3.  Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Walter Ageno; Alexander S Gallus; Ann Wittkowsky; Mark Crowther; Elaine M Hylek; Gualtiero Palareti
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

4.  The need for an adapted initiation nomogram during Fiix prothrombin time monitoring of warfarin.

Authors:  Pall T Onundarson; Brynja R Gudmundsdottir
Journal:  J Thromb Thrombolysis       Date:  2019-11       Impact factor: 2.300

5.  Reduced anticoagulation variability in patients on warfarin monitored with Fiix-prothrombin time associates with reduced thromboembolism: The Fiix-trial.

Authors:  Alma Rut Oskarsdóttir; Brynja R Gudmundsdottir; Olafur S Indridason; Sigrun H Lund; David O Arnar; Einar S Bjornsson; Magnus K Magnusson; Hulda M Jensdottir; Brynjar Vidarsson; Charles W Francis; Pall T Onundarson
Journal:  J Thromb Thrombolysis       Date:  2017-05       Impact factor: 2.300

6.  Tissue factor initiates glomerular fibrin deposition and promotes major histocompatibility complex class II expression in crescentic glomerulonephritis.

Authors:  J H Erlich; S R Holdsworth; P G Tipping
Journal:  Am J Pathol       Date:  1997-03       Impact factor: 4.307

7.  Mechanisms of vascular permeability and remodeling associated with hemarthrosis in factor VIII-deficient mice.

Authors:  Esther J Cooke; Tine Wyseure; Jenny Y Zhou; Srila Gopal; Chanond A Nasamran; Kathleen M Fisch; Tina Manon-Jensen; Morten A Karsdal; Laurent O Mosnier; Annette von Drygalski
Journal:  J Thromb Haemost       Date:  2019-08-09       Impact factor: 5.824

Review 8.  Anticoagulation therapy in children.

Authors:  Milind D Ronghe; Christina Halsey; Nicholas J Goulden
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

9.  The anticoagulant, antithrombotic and haemorrhagic effect of long-term warfarin on experimental venous and arterial thrombosis in the rat.

Authors:  M MacIomhair; S M Lavelle
Journal:  Ir J Med Sci       Date:  1996 Jul-Sep       Impact factor: 1.568

10.  Pharmacometric modeling to explore 4F-PCC dosing strategies for VKA reversal in patients with INR below 2.

Authors:  Ravi Sarode; Katsuyuki Fukutake; Masahiro Yasaka; Michael A Tortorici; Antoinette Mangione; Marc Pfister; Adam Cuker
Journal:  Blood Adv       Date:  2020-09-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.